Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-stage lung cancer

Marta Scorsetti, P. Navarria, A. Facoetti, P. Lattuada, G. Urso, A. Mirandola, G. M. Ferraroli, M. Alloisio, G. Ravasi

Research output: Contribution to journalArticle

Abstract

Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Stereotactic body irradiation offers a non-invasive treatment modality for patients with early stage NSCLC who are not amenable to surgery or other invasive approaches because of their poor medical condition. Patients and Methods: Forty-three inoperable patients with NSCLC were treated with SBRT at our institution. A mean total dose of 30.5 Gy in 1-4 fractions was applied. The median follow-up duration was 14 months (range 6-36 months). Results: The actuarial survival at two years was 53%: two patients died from cancer progression whereas a further 8 patients died from comorbidities. Acute toxicity was practically absent, with 7 (16.3%) patients suffering from grade 1 symptoms and two from (4.6%) grade II effects. At the time of this report, only 1 patient had grade II and 6 patients (13.9%) grade I chronic symptoms. Conclusion: Our results compare favourably with recently published studies and confirm that stereotactic radiotherapy has the potential to produce high local control rates with a low risk of lung toxicity in patients not amenable to curative resection. The low grade of side-effects is encouraging for shortening the treatment using a greater dose per fraction.

Original languageEnglish
Pages (from-to)3615-3619
Number of pages5
JournalAnticancer Research
Volume27
Issue number5 B
Publication statusPublished - Sep 2007

Fingerprint

Radiosurgery
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Therapeutics
Comorbidity
Cause of Death
Neoplasms
Radiotherapy
Lung
Survival

Keywords

  • Normal tissue toxicity
  • NSCLC
  • Radiotherapy
  • SBRT
  • Tumour response

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Scorsetti, M., Navarria, P., Facoetti, A., Lattuada, P., Urso, G., Mirandola, A., ... Ravasi, G. (2007). Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-stage lung cancer. Anticancer Research, 27(5 B), 3615-3619.

Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-stage lung cancer. / Scorsetti, Marta; Navarria, P.; Facoetti, A.; Lattuada, P.; Urso, G.; Mirandola, A.; Ferraroli, G. M.; Alloisio, M.; Ravasi, G.

In: Anticancer Research, Vol. 27, No. 5 B, 09.2007, p. 3615-3619.

Research output: Contribution to journalArticle

@article{f9ba9b70c89e4cc18ad627b4c184f6de,
title = "Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-stage lung cancer",
abstract = "Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Stereotactic body irradiation offers a non-invasive treatment modality for patients with early stage NSCLC who are not amenable to surgery or other invasive approaches because of their poor medical condition. Patients and Methods: Forty-three inoperable patients with NSCLC were treated with SBRT at our institution. A mean total dose of 30.5 Gy in 1-4 fractions was applied. The median follow-up duration was 14 months (range 6-36 months). Results: The actuarial survival at two years was 53{\%}: two patients died from cancer progression whereas a further 8 patients died from comorbidities. Acute toxicity was practically absent, with 7 (16.3{\%}) patients suffering from grade 1 symptoms and two from (4.6{\%}) grade II effects. At the time of this report, only 1 patient had grade II and 6 patients (13.9{\%}) grade I chronic symptoms. Conclusion: Our results compare favourably with recently published studies and confirm that stereotactic radiotherapy has the potential to produce high local control rates with a low risk of lung toxicity in patients not amenable to curative resection. The low grade of side-effects is encouraging for shortening the treatment using a greater dose per fraction.",
keywords = "Normal tissue toxicity, NSCLC, Radiotherapy, SBRT, Tumour response",
author = "Marta Scorsetti and P. Navarria and A. Facoetti and P. Lattuada and G. Urso and A. Mirandola and Ferraroli, {G. M.} and M. Alloisio and G. Ravasi",
year = "2007",
month = "9",
language = "English",
volume = "27",
pages = "3615--3619",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 B",

}

TY - JOUR

T1 - Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-stage lung cancer

AU - Scorsetti, Marta

AU - Navarria, P.

AU - Facoetti, A.

AU - Lattuada, P.

AU - Urso, G.

AU - Mirandola, A.

AU - Ferraroli, G. M.

AU - Alloisio, M.

AU - Ravasi, G.

PY - 2007/9

Y1 - 2007/9

N2 - Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Stereotactic body irradiation offers a non-invasive treatment modality for patients with early stage NSCLC who are not amenable to surgery or other invasive approaches because of their poor medical condition. Patients and Methods: Forty-three inoperable patients with NSCLC were treated with SBRT at our institution. A mean total dose of 30.5 Gy in 1-4 fractions was applied. The median follow-up duration was 14 months (range 6-36 months). Results: The actuarial survival at two years was 53%: two patients died from cancer progression whereas a further 8 patients died from comorbidities. Acute toxicity was practically absent, with 7 (16.3%) patients suffering from grade 1 symptoms and two from (4.6%) grade II effects. At the time of this report, only 1 patient had grade II and 6 patients (13.9%) grade I chronic symptoms. Conclusion: Our results compare favourably with recently published studies and confirm that stereotactic radiotherapy has the potential to produce high local control rates with a low risk of lung toxicity in patients not amenable to curative resection. The low grade of side-effects is encouraging for shortening the treatment using a greater dose per fraction.

AB - Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Stereotactic body irradiation offers a non-invasive treatment modality for patients with early stage NSCLC who are not amenable to surgery or other invasive approaches because of their poor medical condition. Patients and Methods: Forty-three inoperable patients with NSCLC were treated with SBRT at our institution. A mean total dose of 30.5 Gy in 1-4 fractions was applied. The median follow-up duration was 14 months (range 6-36 months). Results: The actuarial survival at two years was 53%: two patients died from cancer progression whereas a further 8 patients died from comorbidities. Acute toxicity was practically absent, with 7 (16.3%) patients suffering from grade 1 symptoms and two from (4.6%) grade II effects. At the time of this report, only 1 patient had grade II and 6 patients (13.9%) grade I chronic symptoms. Conclusion: Our results compare favourably with recently published studies and confirm that stereotactic radiotherapy has the potential to produce high local control rates with a low risk of lung toxicity in patients not amenable to curative resection. The low grade of side-effects is encouraging for shortening the treatment using a greater dose per fraction.

KW - Normal tissue toxicity

KW - NSCLC

KW - Radiotherapy

KW - SBRT

KW - Tumour response

UR - http://www.scopus.com/inward/record.url?scp=35349015811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35349015811&partnerID=8YFLogxK

M3 - Article

C2 - 17972525

AN - SCOPUS:35349015811

VL - 27

SP - 3615

EP - 3619

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 B

ER -